Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in EGFRm-positive Stage II-IIIB NSCLC Following Complete Tumour Resection
NCT05526755Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2023
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung carcinoma (NSCLC), sponsored by AstraZeneca. Primary endpoint: Disease Free Survival at 5 years. Started Mar 2023; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT05526755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526755.